398 related articles for article (PubMed ID: 32749053)
1. Prognostic factors in medically inoperable early stage lung cancer patients treated with stereotactic ablative radiation therapy (SABR): Turkish Radiation Oncology Society Multicentric Study.
Sahin B; Atalar B; Kaytan Saglam E; Akgun Z; Abacioglu U; Arifoglu A; Ozyar E; Yaprak G; Ozseker Isik N; Guney Y; Caglar HB; Karaman S; Igdem S; Selek U; Berber T; Oner Dincbas F; Sengoz M; Yucel S; Demiral AN; Akyurek S
Clin Respir J; 2020 Nov; 14(11):1050-1059. PubMed ID: 32749053
[TBL] [Abstract][Full Text] [Related]
2. A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy.
Grills IS; Hope AJ; Guckenberger M; Kestin LL; Werner-Wasik M; Yan D; Sonke JJ; Bissonnette JP; Wilbert J; Xiao Y; Belderbos J
J Thorac Oncol; 2012 Sep; 7(9):1382-93. PubMed ID: 22843086
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic Ablative Radiation Therapy for Large (≥5 cm) Non-small Cell Lung Carcinoma.
McDermott RL; Mihai A; Dunne M; Keys M; O'Sullivan S; Thirion P; ElBeltagi N; Armstrong JG
Clin Oncol (R Coll Radiol); 2021 May; 33(5):292-299. PubMed ID: 33309479
[TBL] [Abstract][Full Text] [Related]
4. Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy.
Zhao L; Zhou S; Balter P; Shen C; Gomez DR; Welsh JD; Lin SH; Chang JY
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1226-35. PubMed ID: 27209498
[TBL] [Abstract][Full Text] [Related]
5. Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) - An analysis of UK's largest cohort of lung SABR patients.
Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
Radiother Oncol; 2021 Mar; 156():153-159. PubMed ID: 33333139
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
[TBL] [Abstract][Full Text] [Related]
7. Correlation of biologically effective dose and the tumor control in Stage I (<5 cm) non-small cell lung cancer with stereotactic ablative radiotherapy: a single institutional cohort study.
Jeon W; Ahn SJ; Kim YC; Oh IJ; Park CK; Jeong JU; Yoon MS; Song JY; Nam TK; Chung WK
Jpn J Clin Oncol; 2018 Feb; 48(2):144-152. PubMed ID: 29194510
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080
[TBL] [Abstract][Full Text] [Related]
9. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer.
Chang JY; Liu H; Balter P; Komaki R; Liao Z; Welsh J; Mehran RJ; Roth JA; Swisher SG
Radiat Oncol; 2012 Sep; 7():152. PubMed ID: 22963661
[TBL] [Abstract][Full Text] [Related]
11. Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.
Kelley KD; Benninghoff DL; Stein JS; Li JZ; Byrnes RT; Potters L; Knisely JP; Zinkin HD
Radiat Oncol; 2015 May; 10():120. PubMed ID: 26018408
[TBL] [Abstract][Full Text] [Related]
12. Survival analysis after stereotactic ablative radiotherapy for early stage non-small cell lung cancer: a single-institution cohort study.
Resova K; Knybel L; Parackova T; Rybar M; Cwiertka K; Cvek J
Radiat Oncol; 2024 Apr; 19(1):50. PubMed ID: 38637844
[TBL] [Abstract][Full Text] [Related]
13. Late Toxicity and Long-Term Local Control in Patients With Ultra-Central Lung Tumours Treated by Intensity-Modulated Radiotherapy-Based Stereotactic Ablative Body Radiotherapy With Homogenous Dose Prescription.
Mihai AM; Armstrong PJ; Hickey D; Milano MT; Dunne M; Healy K; Thirion P; Heron DE; ElBeltagi N; Armstrong JG
Clin Oncol (R Coll Radiol); 2021 Oct; 33(10):627-637. PubMed ID: 34092462
[TBL] [Abstract][Full Text] [Related]
14. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
[TBL] [Abstract][Full Text] [Related]
15. Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer?
Bilal H; Mahmood S; Rajashanker B; Shah R
Interact Cardiovasc Thorac Surg; 2012 Aug; 15(2):258-65. PubMed ID: 22581864
[TBL] [Abstract][Full Text] [Related]
16. Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location.
Schonewolf CA; Heskel M; Doucette A; Singhal S; Frick MA; Xanthopoulos EP; Corradetti MN; Friedberg JS; Pechet TT; Christodouleas JP; Levin W; Berman A; Cengel KA; Verma V; Hahn SM; Kucharczuk JC; Rengan R; Simone CB
Clin Lung Cancer; 2019 Jan; 20(1):e63-e71. PubMed ID: 30337269
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic ablative body radiation therapy for octogenarians with non-small cell lung cancer.
Takeda A; Sanuki N; Eriguchi T; Kaneko T; Morita S; Handa H; Aoki Y; Oku Y; Kunieda E
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):257-63. PubMed ID: 23570699
[TBL] [Abstract][Full Text] [Related]
18. Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non-small-cell Lung Cancer.
Lee S; Song SY; Kim SS; Choi W; Je HU; Back GM; Cho B; Jeong SY; Choi EK
Clin Lung Cancer; 2018 Mar; 19(2):e253-e261. PubMed ID: 29196082
[TBL] [Abstract][Full Text] [Related]
19. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.
Sun B; Brooks ED; Komaki R; Liao Z; Jeter M; McAleer M; Balter PA; Welsh JD; O'Reilly M; Gomez D; Hahn SM; Sepesi B; Rice DC; Heymach JV; Chang JY
J Thorac Oncol; 2017 Jun; 12(6):983-992. PubMed ID: 28259750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]